-
-
-
-
-
-
-
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
-
-
-
-
-
-
-
H.C. Wainwright Downgrades Avidity Biosciences (RNA) to Neutral Post Novartis Acquisition
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Novartis (NVS)
-
-
-
-
-
-
-
Midday movers: Estee Lauder, Eli Lilly and more
-
-
-
-
-
-
-
This biotech stock is seen as the next takeover with over 100% upside
-
-
-
-
-
-
-
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
-
-
-
-
-
-
-
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
-
1,186,894 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

